Panbela Schedules Conference Call on May 12, 2022, to Report 2022 First Quarter Financial Results
MINNEAPOLIS, April 26, 2022 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical…
News
Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting
IRVINE, Calif., April 26, 2022 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission…
First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial
POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now…
Better Choice Company to Host First Quarter 2022 Earnings Call on May 12th at 8:30 a.m. ET
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) — Better Choice Company (NYSE: BTTR) (“Better Choice”…
Quotient Limited Announces Appointment of New Board Member
JERSEY, Channel Islands, April 26, 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ: QTNT), a commercial-stage…
Biomerica Announces FDA Submission For a Test to Detect Helicobacter pylori (H. pylori), a Bacteria That Infects Approximately 35% of the US Population
Gastric cancer is the third most common cause of cancer related death in the world…
Codex DNA Demonstrates End-to-End Workflow for Storing and Retrieving Data in Synthetic DNA
Proof-of-concept studies go beyond typical DNA data storage projects to ensure high-fidelity data recovery within…
Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference
Presentations Highlight Topline Results, Sub-Analysis for sulbactam-durlobactam (SUL-DUR) WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE)…
Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022
MENLO PARK, Calif., April 26, 2022 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (“TLIS”), a company…
Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a…
Shape Therapeutics Welcomes Google and Stripe Veterans Gayathri Rajan, Kelly Sims to its Board of Directors
Rajan, Sims bring unique platform technology experience to help build the next generation of RNA…
Agile Therapeutics Announces 1-For-40 Reverse Stock Split
PRINCETON, N.J., April 26, 2022 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile”), a women’s…
Rubius Therapeutics to Announce First Quarter 2022 Financial Results
CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage…
Rhythm Pharmaceuticals to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
BOSTON, April 26, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pancreatic Cancer
CLAUDIO-01 is the first-in-human trial of SOT102, a CLDN18.2 (Claudin 18.2) targeting antibody-drug conjugate (ADC)…
89bio to Host Key Opinion Leader Webinar on Severe Hypertriglyceridemia (SHTG)
Webinar to feature presentations from Harold Bays, MD, and Deepak L. Bhatt, MD, MPH, on…
VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer
FDA grants Fast Track designation to facilitate development and expedite the review of therapies with…
OncoC4 Announces Fast Track Designation Granted by the U.S. FDA for ONC-392 Monotherapy in PD(L)1-Resistant NSCLC
A Phase 1b clinical trial of ONC-392 in PD(L)1-resistant NSCLC is currently underway ROCKVILLE, Md.,…
Athira Files Investor Presentation Highlighting Successful Execution of its Strategy and Highly Qualified Board and Leadership
Urges shareholders to vote “FOR” Athira’s highly qualified, independent director nominees – Joseph Edelman, John…
Optinose Announces Appointment of R. John Fletcher to the Board
YARDLEY, Pa., April 26, 2022 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on…